Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains

Abstract

Objective: Mutations in the glucocerebrosidase gene ( GBA ) represent a significant risk factor for developing Parkinson disease (PD). We investigated the enzymatic activity of glucocerebrosidase (GCase) in PD brains carrying heterozygote GBA mutations (PD+GBA) and sporadic PD brains. Methods: GCase activity was measured using a fluorescent assay in cerebellum, frontal cortex, putamen, amygdala, and substantia nigra of PD+GBA (n = 9–14) and sporadic PD brains (n = 12–14). Protein expression of GCase and other lysosomal proteins was determined by western blotting. The relation between GCase, α‐synuclein, and mitochondria function was also investigated in vitro. Results: A significant decrease in GCase activity was observed in all PD+GBA brain areas except the frontal cortex. The greatest deficiency was in the substantia nigra (58% decrease; p < 0.01). GCase activity was also significantly decreased in the substantia nigra (33% decrease; p < 0.05) and cerebellum (24% decrease; p < 0.05) of sporadic PD brains. GCase protein expression was lower in PD+GBA and PD brains, whereas increased C/EBP homologous protein and binding immunoglobulin protein levels indicated that the unfolded protein response was activated. Elevated α‐synuclein levels or PTEN‐induced putative kinase 1 deficiency in cultured cells had a significant effect on GCase protein levels. Interpretation: GCase deficiency in PD brains with GBA mutations is a combination of decreased catalytic activity and reduced protein levels. This is most pronounced in the substantia nigra. Biochemical changes involved in PD pathogenesis affect wild‐type GCase protein expression in vitro, and these could be contributing factors to the GCase deficiency observed in sporadic PD brains. ANN NEUROL 2012;72:455–463.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 38

1. 1.

   Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372:1263-1271.

   Not in our library10.1016/s0140-6736(08)61522-6

2. 2.

   Schapira AHV. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008;7:97-109.

   Not in our library10.1016/s1474-4422(07)70327-7

3. 3.

   Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996;89:691-694.

   Not in our library10.1093/qjmed/89.9.691

4. 4.

   Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2004;351:1972-1977.

   Not in our library10.1056/nejmoa033277

5. 5.

   Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192-207.

   Not in our library10.1016/j.ymgme.2004.04.011

6. 6.

   Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41:937-940.

   Not in our library10.1136/jmg.2004.024455

7. 7.

   Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010;10:190-198.

   Not in our library10.1007/s11910-010-0102-x

8. 8.

   Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132:1783-1794.

   Not in our library10.1093/brain/awp044

9. 9.

   Cuervo AM, Wong ESP, Martinez-Vicente M. Protein degradation, aggregation, and misfolding. Mov Disord. 2010;25(suppl 1):S49-S54.

   Not in our library10.1002/mds.22718

10. 10.

    Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010;67:1464-1472.

    Not in our library10.1001/archneurol.2010.198

11. 11.

    Dehay B, Bové J, Rodríguez-Muela N, et al. Pathogenic lysosomal depletion in Parkinson's disease. J Neurosci. 2010;30:12535-12544.

    Not in our library10.1523/jneurosci.1920-10.2010

12. 12.

    Cuervo AM, Stefanis L, Fredenburg R, et al. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292-1295.

    Not in our library10.1126/science.1101738

13. 13.

    Gegg ME, Schapira AHV. PINK1-parkin-dependent mitophagy involves ubiquitination of mitofusins 1 and 2: implications for Parkinson disease pathogenesis. Autophagy. 2011;7:243-245.

    Not in our library10.4161/auto.7.2.14332

14. 14.

    Sardi SP, Clarke J, Kinnecom C, et al. CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A. 2011;108:12101-12106.

    Not in our library10.1073/pnas.1108197108

15. 15.

    Xu YH, Sun Y, Ran H, et al. Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. 2011;102:436-447.

    Not in our library10.1016/j.ymgme.2010.12.014

16. 16.

    Manning-Boǧ AB, Schüle B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology. 2009;30:1127-1132.

    Not in our library10.1016/j.neuro.2009.06.009

17. 17.

    Cullen V, Sardi SP, Ng J, et al. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol. 2011;69:940-953.

    Not in our library10.1002/ana.22400

18. 18.

    Mazzulli JR, Xu Y-H, Sun Y, et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37-52.

    Not in our library10.1016/j.cell.2011.06.001

19. 19.

    Yap TL, Gruschus JM, Velayati A, et al. Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem. 2011;286:28080-28088.

    Not in our library10.1074/jbc.m111.237859

20. 20.

    Wenger DA, Clark C, Sattler M, Wharton C. Synthetic substrate beta-glucosidase activity in leukocytes: a reproducible method for the identification of patients and carriers of Gaucher's disease. Clin Genet. 1978;13:145-153.

    Not in our library10.1111/j.1399-0004.1978.tb04242.x

21. 21.

    Boot RG, Verhoek M, Donker-Koopman W, et al. Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem. 2007;282:1305-1312.

    Not in our library10.1074/jbc.m610544200

22. 22.

    Wendeler M, Sandhoff K. Hexosaminidase assays. Glycoconj J. 2009;26:945-952.

    Not in our library10.1007/s10719-008-9137-5

23. 23.

    Klionsky DJ, Abeliovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151-175.

    Not in our library10.4161/auto.5338

24. 24.

    Ron I, Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet. 2005;14:2387-2398.

    Not in our library10.1093/hmg/ddi240

25. 25.

    Mu T-W, Ong DST, Wang Y-J, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell. 2008;134:769-781.

    Not in our library10.1016/j.cell.2008.06.037

26. 26.

    Doyle KM, Kennedy D, Gorman AM, et al. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med. 2011;15:2025-2039.

    Not in our library10.1111/j.1582-4934.2011.01374.x

27. 27.

    Witte MD, Kallemeijn WW, Aten J, et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol. 2010;6:907-913.

    Not in our library10.1038/nchembio.466

28. 28.
    Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells · 2009

    No notice
29. 29.
    PINK1 Is Necessary for Long Term Survival and Mitochondrial Function in Human Dopaminergic Neurons · 2008

    Corrected
30. 30.

    Reczek D, Schwake M, Schröder J, et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase. Cell. 2007;131:770-783.

    Not in our library10.1016/j.cell.2007.10.018

31. 31.

    Choi JH, Stubblefield B, Cookson MR, et al. Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations. Mol Genet Metab. 2011;104:185-188.

    Not in our library10.1016/j.ymgme.2011.06.008

32. 32.

    Cooper AA, Gitler AD, Cashikar A, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006;313:324-328.

    Not in our library10.1126/science.1129462

33. 33.

    Thayanidhi N, Helm JR, Nycz DC, et al. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell. 2010;21:1850-1863.

    Not in our library10.1091/mbc.e09-09-0801

34. 34.

    Lu J, Chiang J, Iyer RR, et al. Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci U S A. 2010;107:21665-21670.

    Not in our library10.1073/pnas.1014376107

35. 35.

    Farfel-Becker T, Vitner E, Dekel H, et al. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet. 2009;18:1482-1488.

    Not in our library10.1093/hmg/ddp061

36. 36.

    Bouman L, Schlierf A, Lutz AK, et al. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress. Cell Death Differ. 2011;18:769-782.

    Not in our library10.1038/cdd.2010.142

37. 37.

    Westerlund M, Belin AC, Anvret A, et al. Cerebellar alpha-synuclein levels are decreased in Parkinson's disease and do not correlate with SNCA polymorphisms associated with disease in a Swedish material. FASEB J. 2008;22:3509-3514.

    Not in our library10.1096/fj.08-110148

38. 38.

    Mann VM, Cooper JM, Krige D, et al. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain. 1992;115:333-342.

    Not in our library10.1093/brain/115.2.333

Cited by papers we hold 32

• GBA Variants and Parkinson Disease: Mechanisms and Treatments · 2022
  No notice
• Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson’s disease and dementia with Lewy bodies · 2021
  No notice
• Lipid Metabolism in the Development and Progression of Vascular Cognitive Impairment: A Systematic Review · 2021
  Not checked
• Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson’s disease · 2021
  No notice
• Glycosphingolipids and neuroinflammation in Parkinson’s disease · 2020
  No notice
• Metabolic alterations in Parkinson’s disease astrocytes · 2020
  No notice
• Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations · 2020
  No notice
• The Emerging Role of the Lysosome in Parkinson’s Disease · 2020
  No notice
• Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinson’s disease · 2019
  Corrected
• Dysfunction of Cellular Proteostasis in Parkinson’s Disease · 2019
  No notice
• The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease · 2019
  No notice
• Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease · 2019
  No notice
• Glucocerebrosidase and its relevance to Parkinson disease · 2019
  No notice
• On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease · 2018
  No notice
• Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic · 2018
  No notice
• Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson’s Disease and Dementia with Lewy Bodies · 2018
  No notice
• Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson’s Disease · 2017
  Not checked
• Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease · 2017
  No notice
• Sphingolipids: membrane microdomains in brain development, function and neurological diseases · 2017
  No notice
• Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models · 2016
  No notice

and 12 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.